Thursday, 19 Jul 2018

You are here

The RheumNow Week in Review – 25 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on IL-1 and pregnancy, contraceptives and the risk of RA, Calprotectin the biomarker, T2T failing, and the loss of a giant in rheumatology.

  1. Data on IL-1 inhibitors and pregnancy: 11 paternal & 31 maternal (23 Anakinra, 8 Cannakinumab) exposures, mosly live births and only  1 renal agenesis/ectopic neurohypophysis.  https://buff.ly/2wstyyA
  2. 435 Nordic JIA pts, Uveitis found in 20.5%; 90% asympt. Predictors of uveitis were ANA+, AHA+, JIA onset <7yrs in girls, not boys  https://buff.ly/2ise342
  3. Study of 215 RA patients Rx with DMARDs & T2T strategy. Serum Calprotectin shown to be strong biomarker; significantly correlated with ESR, CDAI, US Power doppler, Xray progression https://t.co/82YvTFtcAV
  4. 4666 elderly Canadian RA patients, only 59% were deemed to be adherent to biologic therapy, Nonadherent used more steroids https://t.co/kmEmgmmc4p
  5. 55% Americans take prescription medicine; now more than ever. https://t.co/3ytMXHHhVP
  6. Swedish EIRA study: Oral contraceptive use decreases risk of ACPA+ RA. breast feeding has no effect. Ever/past oral contraceptive users have a decreased risk of ACPA-positive RA (OR=0.84) https://t.co/7p9wpfHBJY
  7. Ironwood announces FDA approval of its combo drug lesinurad/allopurinol (Duzallo) in a 200/300 tablet. Could this be useful? https://t.co/lcUZTieKqg
  8. 30 yoF with non itchy, nonpainful palpable purpura lesions on legs & abdomen on/off for last 8 mos. Patient has Hx of HBV Rx with Tenovir. What would you do next?
  9. Leukocytoclastic vasculitis is most commonly caused by antibiotic use (Cipro, Cefazolin ) https://t.co/I893XN737C
  10. Non-Tuberculous Mycobacterial Infections - Diagnosis and Management for the Rheumatologist
  11. IV Golimumab Shines in Psoriatic Arthritis  
  12. Treat-to-Target a Bust with Rheumatologists   
  13. It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk 
  14. Dr. H. Ralph Schumacher (1933-2017) 
  15. Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Proposed Changes for 2019 Medicare Fee Schedule

On July 12th the Centers for Medicare & Medicaid Services (CMS) released its proposed rule changes for the 2019 Medicare physician fee schedule.  This year, CMS has combined the Medicare physician fee schedule proposed rule with recommendations for the Quality Payment Program (QPP), which will be officially published in the Federal Register on July 27.

Trend Towards Fewer Self-Employed Physicians

 

A nationwide survey study analyzed healthcare provider (HCP) employment type (self-employed, employed by private sector, or employed by government) and annual labor earnings (2001 to 2015) and found that the health care landscape is changing with few self-employed practitioners and more being larger organizations. 

The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.

The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)

Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.